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Abstract We have found that the growth of human pancreatic 
cancer cells MIAPaCa-2, induced by human pancreatic phos-
pholipase A2 group I (hPLA2-I), is mediated via its specific 
receptor but not via its catalytic property. The present study 
showed that the activation of mitogen-activated protein kinase 
(MAPK) cascade in MIAPaCa-2 cells is induced by hPLA2-I: 
this digestive enzyme induced phosphorylation of MEK1/2, p44/ 
42 MAPK and ATF-2, and the phosphorylation in the MAPK 
cascade was inhibited after the cells were pre-incubated with a 
selective inhibitor of MEK, PD98059. In addition, this inhibitor 
dose-dependently blocked the hPLA2-I-induced MIAPaCa-2 
proliferation, suggesting that activation of the MAPK cascade 
is essential for the hPLA2-I-induced MIAPaCa-2 proliferation. 
© 1997 Federation of European Biochemical Societies. 
Key words: Arachidonic acid metabolism; H u m a n pancreatic 
phospholipase A 2 ; M A P kinase; MIAPaCa-2 ; Proliferation 
1. Introduction 
Phospholipase A2 (PLA 2 ; E C 3.1.1.4) catalyzes the hydrol-
ysis of the ^«-2-acyl ester bond in glycerophospholipids to 
liberate free fatty acids and lysophospholipids [1]. The mam-
malian 14-kDa extracellular PLA 2 s are classified into two 
types, designated group I (PLA2-I) and group II (PLA2-II) , 
based on their primary structures [2]. PLA 2 - I I , found in the 
extracelluar spaces of some inflammatory regions [3-5], stim-
ulates production of prostaglandin D 2 and E2 in several cells 
and tissues [6,7], suggesting that PLA 2 - I I may play an impor-
tant role in the pathogenesis of inflammatory diseases. 
PLA 2 - I , secreted from pancreatic acinar cells as an inactive 
zymogen, functions as an enzyme digesting glycerophospho-
lipids after cleavage with trypsin [8]. Recent studies have 
shown that PLA 2 - I exists not only in the pancreas, but also 
in non-digestive organs, such as lung or spleen [9,10], suggest-
ing that PLA2-I might have another function besides being a 
digestive enzyme. PLA 2 - I binds to a specific receptor on mam-
malian cells and elicits a variety of biological responses in a 
receptor-mediated manner [11-16]. We have recently found 
that human PLA 2 - I (hPLA2-I) stimulates the growth of a 
human pancreatic cancer cell line, MIAPaCa-2 , via hPLA 2 - I 
binding to the specific receptor but not via hPLA 2-I catalytic 
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Abbreviations: AA, arachidonic acid; DMEM, Dulbecco's modified 
Eagle's medium; FBS, fetal bovine serum; h, human; MAPK, 
mitogen-activated protein kinase; MEK, MAPK or ERK kinase; 
NDGA, nordihydroguaiaretic acid; PAGE, polyacrylamide gel elec-
trophoresis; PLA2-I, group 1 of phospholipase A2; PLA2-II, group II 
of phospholipase A2 ; SDS, sodium dodecyl sulfate 
property [17,18]. The intracellular signal transduction on the 
hPLA2-I-induced cell response, however, remains unclear. 
The activation of mitogen-activated protein kinase 
(MAPK) is catalyzed by M A P K kinase ( M A P K K ) or 
M E K , which phosphorylates M A P K on threonine and tyro-
sine residues [19,20]. M A P K is stimulated by a wide variety of 
hormones, cytokines and growth factors and in turn directs 
the phosphorylation of transcriptional factors [21,22]. This 
M A P K cascade has been suggested to regulate cell responses, 
such as cell growth [23] and differentiation [24]. 
The present study demonstrated that hPLA 2 - I induces 
phosphorylation of M E K 1/2, p44/42 M A P K and ATF-2 in 
MIAPaCa-2 cells when dosed to the culture medium. The 
hPLA2-I-induced phosphorylation was inhibited by a selective 
M E K inhibitor, PD98059. Furthermore, PD98059 dose-de-
pendently blocked the hPLA2-I-induced MIAPaCa-2 prolifer-
ation, suggesting that activation of the M A P K cascade plays 
an important role in the hPLA2-I-induced cell proliferation. 
2. Materials and methods 
2.1. Materials and cell culture 
The mature form of hPLA2-I was purified from human pancreatic 
juice by the method described previously [17,18]. The amino acid 
sequence of the purified material was confirmed by Edman degrada-
tion method using an autosequencer (PSQ-2; Shimadzu, Japan). Anti-
phosphorylated MEK1/2, p44/42 MAPK, p38 MAPK, ATF-2, c-Jun 
and Elkl antibodies were purchased from New England Biolabs, 
USA. A selective inhibitor of MAPK kinase or MEK, designated 
PD98059 (2'-amino-3'-methoxyflavone), was obtained from Calbio-
chem-Novabiochem, USA. Indomethacin and nordihydroguaiaretic 
acid (NDGA) were purchased from Wako Pure Chemical Industries, 
Japan, and Sigma Chemical, USA, respectively. PD98059, indometha-
cin or NDGA was dissolved in dimethyl sulfoxide. MIAPaCa-2 cell 
line was supplied by the Japanese Cancer Research Resources Bank 
and maintained in Dulbecco's modified Eagle's medium (DMEM; 
Gibco-BRL, USA) containing 10% fetal bovine serum (FBS; Gibco-
BRL), 100 U/ml penicillin G (Sigma Chemical) and 100 ug/ml strep-
tomycin (Sigma Chemical). The cells were grown in plastic flasks in a 
humidified atmosphere of 5% C0 2 and 95% air at 37°C. 
2.2. Cell proliferation assays 
The cell proliferation assay was performed by the method described 
previously [17,18]. MIAPaCa-2 (2.5 X 104) cells were grown for 24 h in 
0.6 cm2 in a 96-well plate using DMEM supplemented with 10% FBS. 
After the culture medium was replaced with the fresh same medium 
containing 0.1% FBS, the cells were grown in the same medium sup-
plemented with or without hPLA2-I. After incubation for 48 h, the 
cell proliferation was assayed using a Cell Counting Kit (Dojindo 
Laboratories, Japan). The absorbance at 450 nm of aliquots of super-
natant from MIAPaCa-2 cells was measured using an automatic plate 
analyzer (ETY-3A; Toyo Sokki, Japan). 
2.3. Arachidonic acid and its metabolites release assays 
After MIAPaCa-2 (3.0 X 104) cells were grown for 24 h in DMEM 
containing 10% FBS using a 24-well plate, the culture medium was 
replaced with 0.5 ml of the fresh same medium containing 18.5 kBq 
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(0.5 uCi) of [3H]arachidonic acid (AA; 7.77 Tbq/mmol; 210 Ci/mmol; 
Moravek Biochemicals, USA) and followed by incubation for 20 h. 
The 3H-labeled cells were washed twice with DMEM containing 0.1% 
FBS and incubated in the same medium supplemented with or with-
out 50 nM I1PLA2-I. After incubation for the given times, the culture 
medium was aspirated and centrifuged to remove the debris. [3H] 
radioactivity contained in the supernatant was measured in a liquid 
scintillation counter. The cell-associated radioactivity was also meas-
ured after lysing the cells with 0.5% Triton X-100. The amount of 
[3H]AA released in the medium was normalized as the percentage of 
the total incorporated radioactivity (i.e. radioactivity associated with 
the cell plus that released in the medium). 
2.4. Immunoblot analysis of phosphorylated kinases and transcritional 
factors 
MIAPaCa-2 cells, treated with 50 nM hPLA2-I for varying lengths 
of time, were lysed with a lysis buffer consisting of 100 mM Tris-HCl 
(pH 6.8), 4% sodium dodecyl sulfate (SDS), 12% glycerol, 4% 2-mer-
captoethanol and 0.1% bromophenol blue. The lysates were boiled at 
100°C for 5 min, and the 40-ug protein aliquots were subjected to 10% 
SDS-polyacrylamide gel electrophoresis (PAGE). Proteins were elec-
trophoretically transferred to a PVDF membrane (pore size 0.2 urn; 
Bio-Rad Laboratories, USA). Detections of phosphorylated kinases 
and transcritional factors were done using PhosphoPlus Antibody Kit 
series (New England Biolabs) and visualized by exposing to X-ray 
films (Ffyperfilm-MP, Amersham International, UK). 
2.5. Immunocytochemistry 
MIAPaCa-2 cells, treated with or without 50 nM hPLA2-I for 15 
min, were fixed with 4% paraformaldehyde at 4°C for 10 min. The 
fixative was aspirated and the resulting cells were washed 3 X for 5 min 
with 1 ml of TBST solution consisting of 50 mM Tris-HCl (pH 7.4), 
150 mM NaCl and 0.1% Triton X-100. The fixed cells were incubated 
with 1 ml of TBST containing 1.5% normal goat serum. Localization 
of the phosphorylated p44/42 MAPK in the MIAPaCa-2 cells was 
detected using both a PhosphoPlus MAPK Antibody Kit (New 
England Biolabs) and a Vectastain ABC Kit (Vector Laboratories, 
USA). 
3. Results and discussion 
3.1. hPLAi-I induces liberation of AA and its metabolites from 
MIAPaCa-2 cells 
Previous studies have shown that the release of A A and its 
metabolites from mammalian cells is induced by porcine 
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Fig. 1. [3H]AA and its metabolites released from MIAPaCa-2 cells 
treated with or without hPLA2-I. The amount of [3H]AA and its 
metabolites released in the medium was normalized as the percent-
age of the total [3H] radioactivity incorporated into the cells. The 
amounts of the specific release (•) was calculated by subtracting the 
basal amount ( A ) obtained without hPLA2-I from the amount (o) 
with 50 nM hPLA2-I. The data are expressed as the mean of tripli-
cate measurements. 
In the present study, we examined whether I1PLA2-I induces 
the release of AA and its metabolites from MIAPaCa-2 cells. 
Prolonged incubation (48 h) of MIAPaCa-2 cells with 50 n M 
hPLA 2 - I significantly increased their basal release, whereas 
short-term incubation ( < 12 h) did not (Fig. 1). We have 
previously shown that I1PLA2-I (50 nM) stimulates the growth 
of MIAPaCa-2 cells, which is mediated via its hPLA2-I-spe-
cific receptor [17,18]. Since the metabolites derived from AA 
have been suggested to play an important role in cell prolif-
eration [25,26], we tried to examine whether the release of A A 
and its metabolites from MIAPaCa-2 cells, induced by 
hPLA2-I, gives rise to the cell proliferation. Cell responses, 
Fig. 2. hPLA2-I-induced phosphorylation of p44/42 MAPK, MEKl/2 and ATF-2. MIAPaCa-2 cells were incubated with 50 nM hPLA2-I for 
given times. The cell lysates were subjected to SDS-PAGE followed by immunoblotting with anti-phosphorylated p44/42 MAPK (A), with anti-
non-phosphorylated p44/42 MAPK antibody (B); with anti-phosphorylated MEKl/2 antibody (C); with anti-non-phosphorylated MEKl/2 anti-
body (D); with anti-phosphorylated ATF-2 antibody (E) and with anti-non-phosphorylated ATF-2 antibody (F), respectively. 
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Fig. 3. Translocation of the phosphorylated p44/42 MAPK to the 
nuclei after incubation of MIAPaCa-2 cells with hPLA2-I. A or B 
indicates light micrograph of the cells incubated without or with 50 
nM hPLA2-I, respectively. Bar, 10 |im. 
stimulated by AA metabolites liberated from the cell mem-
brane, are known to be blocked by indomethacin and nordi-
hydroguaiaretic acid (NDGA) [14,26,27]. We found that the 
hPLA2-I-induced proliferativity on MIAPaCa-2 cells is the 
same as that without indomethacin or NDGA, even when 
treated with each inhibitor (data not shown). These results 
suggest that the AA metabolic pathway may not contribute 
to the hPLA2-I-induced cell proliferation. 
for 15 min (Fig. 3B). On the other hand, phosphorylation of 
p38 MAPK, which may be activated under some stress, did 
not occur in MIAPaCa-2 cells treated with 50 nM hPLA2-I 
(data not shown). 
We investigated phosphorylation of MEK1/2 in the MIA-
PaCa-2 cells treated with 50 nM hPLA2-I. MEK1/2 are dual-
specific kinases and phosphorylate threonine and tyrosine res-
idues in p44/42 MAPK [19,20]. Fig. 2C shows that the phos-
phorylated MEK1/2 increased clearly within at least 5 min 
and decreased to the basal level within 60 min. As described 
above, no detectable change in the total amounts of protein 
per each lane was noted (Fig. 2D). In addition, we investi-
gated phosphorylation of transcriptional factors after treat-
ment of MIAPaCa-2 cells with 50 nM hPLA2-I. MAPK, ac-
tivated by a wide variety of stimulants, directs the 
phosphorylation of transcriptional factors, such as c-Jun 
and TCF [21,22]. Fig. 2E shows that the phosphorylated 
ATF-2 was obviously detected at 10-30 min and decreased 
to the basal level within 60 min. However, transcriptional 
factors, such as c-Jun and Elkl, were not phosphorylated in 
MIAPaCa-2 cells by addition of 50 nM hPLA2-I (data not 
shown). 
3.2. Phosphorylation of MEK1I2, p44l42 MAPK and ATF-2 
induced by hPLAi-I 
To evaluate activation of MAPK cascade, induced by 
hPLA2-I, we examined whether MAPK in MIAPaCa-2 cells 
is phosphorylated when hPLA2-I is added to the culture me-
dium. MIAPaCa-2 cells were incubated in DMEM containing 
0.1% FBS with or without 50 nM hPLA2-I for the given 
times. The cells were lysed, and the resulting lysates were 
subjected to an immunoblot analysis using an anti-phosphory-
lated p44/42 MAPK antibody. Fig. 2A shows that the phos-
phorylated p44/42 MAPK was detectable within at least 10 
min and disappeared within 180 min, after addition of 
hPLA2-I. Total amounts of protein (Fig. 2B), detected by 
using anti-non-phosphorylated p44/42 MAPK antibody, did 
not change with different incubation periods. We observed 
that the phosphorylated p44/42 MAPK translocates to the 
nuclei in the MIAPaCa-2 cells treated with 50 nM hPLA2-I 
Fig. 4. Effects of PD98059 on the hPLA2-I-induced phosphorylation 
of MEK1/2, p44/42 MAPK and ATF-2, and cell viability. The cells 
were treated with 50 uM PD98059 for 16 h before the addition of 
50 nM hPLA2-I for desired time. Immunoblot analyses with anti-
phosphorylated MEK1/2 (A), anti-phosphorylated p44/42 MAPK 
(B) and anti-phosphorylated ATF-2 antibodies (C). (D) indicates vi-
ability of MIAPaCa-2 cells incubated with 50 nM hPLA2-I for 2 h 
after pre-treatment with PD98059 for 16 h. The data are expressed 
as the mean and the standard deviation of triplicate measurements. 
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Fig. 5. Dose effects of PD98059 on the hPLA2-I-induced MIAPaCa-
2 proliferation. The cells were incubated with 50 nM hPLA2-I for 
48 h after pre-treatment with various concentrations of PD98059 
for 16 h. The data are expressed as the mean and the standard devi-
ation of triplicate measurements. UT; untreated with hPLA2T and 
PD98059. 
3.3. MAPK cascade required for hPLA2-I-induced MIPaCa-2 
proliferation 
PD98059 blocks phosphorylation of M A P K and several cell 
responses, which are mediated via the M A P K cascade [24,28]. 
We examined the effect of PD98059 on the phosphorylation 
of MEK1/2 , p44/42 M A P K and ATF-2 in MIAPaCa-2 cells, 
which are induced by hPLA 2 - I . After the cells were incubated 
with 50 m M PD98059 for 16 h prior to the treatment with 50 
u,M I1PLA2-I for the given times, the cell lysates were sub-
jected to SDS-PAGE, and followed by immunoblott ing with 
anti-phosphorylated antibodies. Fig. 4 A - D shows that all 
phosphorylation of MEK1/2 , p44/42 M A P K and ATF-2, 
which are induced by I1PLA2-I, were completely inhibited by 
pre-treatment with PD98059 without altering cell viability. 
To evaluate the significant role of the M E K - M A P K path-
way in the hPLA2-Tinduced cell proliferation, MIAPaCa-2 
cells were treated with various concentrations of PD98059 
for 16 h before addition of 50 n M hPLA 2 - I . As shown in 
Fig. 5, PD98059 dose-dependently blocked the hPLA2-I- in-
duced MIAPaCa-2 proliferation. These data provide a strong 
support for the requirement of activation of the M A P K cas-
cade in the hPLA2-Tinduced cell proliferation. 
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